PROTARA THERAPEUTIC INC (TARA) Fundamental Analysis & Valuation

NASDAQ:TARA • US74365U1079

5.71 USD
-0.11 (-1.89%)
Last: Mar 6, 2026, 12:13 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TARA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, TARA scores 3 out of 10 in our fundamental rating. TARA was compared to 520 industry peers in the Biotechnology industry. While TARA has a great health rating, there are worries on its profitability. TARA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. TARA Profitability Analysis

1.1 Basic Checks

  • TARA had negative earnings in the past year.
  • In the past year TARA has reported a negative cash flow from operations.
  • TARA had negative earnings in each of the past 5 years.
  • In the past 5 years TARA always reported negative operating cash flow.
TARA Yearly Net Income VS EBIT VS OCF VS FCFTARA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • TARA's Return On Assets of -36.58% is fine compared to the rest of the industry. TARA outperforms 60.58% of its industry peers.
  • Looking at the Return On Equity, with a value of -39.99%, TARA is in the better half of the industry, outperforming 69.81% of the companies in the same industry.
Industry RankSector Rank
ROA -36.58%
ROE -39.99%
ROIC N/A
ROA(3y)-44.56%
ROA(5y)-35.55%
ROE(3y)-50.02%
ROE(5y)-39.26%
ROIC(3y)N/A
ROIC(5y)N/A
TARA Yearly ROA, ROE, ROICTARA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • TARA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TARA Yearly Profit, Operating, Gross MarginsTARA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. TARA Health Analysis

2.1 Basic Checks

  • TARA has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, TARA has more shares outstanding
  • There is no outstanding debt for TARA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TARA Yearly Shares OutstandingTARA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
TARA Yearly Total Debt VS Total AssetsTARA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • TARA has an Altman-Z score of 11.52. This indicates that TARA is financially healthy and has little risk of bankruptcy at the moment.
  • TARA has a better Altman-Z score (11.52) than 83.85% of its industry peers.
  • TARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.52
ROIC/WACCN/A
WACCN/A
TARA Yearly LT Debt VS Equity VS FCFTARA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • TARA has a Current Ratio of 13.69. This indicates that TARA is financially healthy and has no problem in meeting its short term obligations.
  • TARA has a Current ratio of 13.69. This is amongst the best in the industry. TARA outperforms 89.42% of its industry peers.
  • TARA has a Quick Ratio of 13.69. This indicates that TARA is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 13.69, TARA belongs to the best of the industry, outperforming 89.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.69
Quick Ratio 13.69
TARA Yearly Current Assets VS Current LiabilitesTARA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. TARA Growth Analysis

3.1 Past

  • TARA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.94%, which is quite impressive.
EPS 1Y (TTM)48.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • TARA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.67% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y47.1%
EPS Next 2Y18.93%
EPS Next 3Y8.78%
EPS Next 5Y14.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TARA Yearly Revenue VS EstimatesTARA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
TARA Yearly EPS VS EstimatesTARA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

0

4. TARA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TARA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TARA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TARA Price Earnings VS Forward Price EarningsTARA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TARA Per share dataTARA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.93%
EPS Next 3Y8.78%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TARA Dividend Analysis

5.1 Amount

  • No dividends for TARA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TARA Fundamentals: All Metrics, Ratios and Statistics

PROTARA THERAPEUTIC INC

NASDAQ:TARA (3/6/2026, 12:13:19 PM)

5.71

-0.11 (-1.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-11
Inst Owners50.95%
Inst Owner Change48.96%
Ins Owners2.11%
Ins Owner Change6.85%
Market Cap294.81M
Revenue(TTM)N/A
Net Income(TTM)-52.90M
Analysts83.08
Price Target26.01 (355.52%)
Short Float %6.57%
Short Ratio3.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.06%
Min EPS beat(2)15.27%
Max EPS beat(2)20.85%
EPS beat(4)4
Avg EPS beat(4)22.05%
Min EPS beat(4)14.97%
Max EPS beat(4)37.1%
EPS beat(8)7
Avg EPS beat(8)17.41%
EPS beat(12)9
Avg EPS beat(12)4.01%
EPS beat(16)12
Avg EPS beat(16)4.84%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.68%
PT rev (3m)2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.14%
EPS NY rev (1m)1.45%
EPS NY rev (3m)9.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.23
P/tB 2.23
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS0
BVpS2.56
TBVpS2.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -36.58%
ROE -39.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.56%
ROA(5y)-35.55%
ROE(3y)-50.02%
ROE(5y)-39.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -18.3%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.69
Quick Ratio 13.69
Altman-Z 11.52
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)26.72%
Cap/Depr(5y)292.03%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38%
EPS Next Y47.1%
EPS Next 2Y18.93%
EPS Next 3Y8.78%
EPS Next 5Y14.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-29.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.29%
OCF growth 3YN/A
OCF growth 5YN/A

PROTARA THERAPEUTIC INC / TARA FAQ

What is the fundamental rating for TARA stock?

ChartMill assigns a fundamental rating of 3 / 10 to TARA.


What is the valuation status of PROTARA THERAPEUTIC INC (TARA) stock?

ChartMill assigns a valuation rating of 0 / 10 to PROTARA THERAPEUTIC INC (TARA). This can be considered as Overvalued.


What is the profitability of TARA stock?

PROTARA THERAPEUTIC INC (TARA) has a profitability rating of 1 / 10.


What is the financial health of PROTARA THERAPEUTIC INC (TARA) stock?

The financial health rating of PROTARA THERAPEUTIC INC (TARA) is 8 / 10.